# Medtronic

Resolute Integrity

ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM

Strong Performance in Diabetics in the RESOLUTE Clinical Program*

## No significant difference in TLF rates in diabetics vs. nondiabetics

RESOLUTE Pooled Analysis, 12-Month Data

Diabetes (N = 878)
Nondiabetes (N = 1903)

Cumulative Incidence of TLF (%)

6.6
4.9

Time After Initial Procedure (days)

Low TLR rates in diabetics

Excellent efficacy results in challenging diabetic patient group

TLR Rates, RESOLUTE Pooled Analysis, 12-Month Data

(%)

Overall (n = 2734)	Nondiabetics (n = 1867)	Diabetics (DM) (n = 867)	Noninsulin-Dependent DM (n = 621)	Insulin-Dependent DM (n = 246)
2.5	2.0	3.3	2.6	5.3

Powerful performance across all clinical endpoints

Large number of diabetics studied in the RESOLUTE clinical program

RESOLUTE Diabetic Pooled Analysis, 12-Month Data
(n = 867)

(%)

TVF	CD-TVR	Cardiac Death	TV MI	ARC Def/Prob ST
8.1	5.1	2.0	1.8	0.3

*Only includes on-label diabetic patients from RESOLUTE pooled analysis (R-FIM: 24 pts, R-AC, R-ZES: 85 pts, R-Int: 242 pts, R-US: 482 pts, R-J: 45 pts). RESOLUTE trials evaluated the Resolute stent. Other than TVF, RESOLUTE pooled analysis was not specifically designed or powered to evaluate the endpoints shown above.

Strong Performance in Real-World Diabetics in Independent, Investigator-Initiated Study*

Study included real-world, challenging patients

Higher percentage of challenging patients in diabetic arm

Patient Baseline Characteristics from RISICO Study Group All-Comer Registry	Diabetic Patients (N = 271)	Nondiabetic Patients (N = 584)	p-Value
Age (yr)	67.2 ± 9.4	64.6 ± 10.8	$p < 0.0001$
Hypertension (%)	87.1	72.8	$p < 0.0001$
IDDM (%)	16.4	–	–
ACS (%)	46.6	46.1	0.89
Multivessel disease (%)	23	22.3	0.80
CTO (%)	8.2	8.2	0.97
B2/C (%)	66.9	72.2	0.78
Bifurcations (%)	26.1	33.3	0.01
Left main (%)	3.4	3.8	0.69
SVG	1.7	2.3	0.50
Lesion Characteristics			
Mean stent diameter (mm)	2.9 ± 0.5	3.0 ± 0.4	0.002
Total stent length (mm)	28.7 ±17.7	26.2 ± 14.7	0.037

Strong performance in diabetic all-comers patients

No significant difference in real-world diabetic vs. nondiabetic group

RISICO Study Group (Dr. A Ielasi et al.), 15-Month Data

Diabetic Patients (n = 293)
Nondiabetic Patients (n = 603)

(%)

MACE (D/MI/TVR): Nondiabetic 6.4, Diabetic 11.2, $p = 0.74$
TLF (CD/TVMI/TLR): Nondiabetic 3.7, Diabetic 5.0, $p = 0.97$
TLR: Nondiabetic 2.3, Diabetic 3.5, $p = 0.76$
Cardiac Death/MI: Nondiabetic 1.9, Diabetic 2.9, $p = 0.27$
ARC Def/Prob ST: Nondiabetic 0.6, Diabetic 1.4, $p = 0.1$

*Retrospective Analysis of Clinical Outcomes in Diabetic and Nondiabetic Patients Treated with Resolute Zotarolimus-Eluting Stent: A Multicentre Italian Evaluation, A Ielasi. The study evaluated the Resolute stent. Study supported by Medtronic, Inc.

The Simple Choice in Diabetics

Resolute Integrity
ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM

Make the Complex Simple

Resolute Integrity DES now has expanded indications for diabetes mellitus, multivessel disease, long lesions and small vessels.

www.medtronic.com
www.medtronicstents.com

Europe
Medtronic Intl. Trading SARL
Route du Molliau 31
Case Postale
CH-1131 Tolochenaz
Switzerland
Tel: +(41) 21.802.7000
Fax: +(41) 21.802.7900

Asia Pacific
Medtronic Intl. Ltd.
16/F Manulife Plaza
The Lee Gardens
33 Hysan Avenue
Causeway Bay
Hong Kong
Tel: +(852) 2919.1300
Fax: +(852) 2891.6830
enquiryap@medtronic.com

Latin America
Medtronic USA, Inc.
Doral Corporate Center II
3750 NW 87th Avenue
Suite 700
Miami, FL 33178
USA
Tel: +1 (305) 500.9328
Fax: +1 (786) 709.4244

Medtronic